Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 10,000 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $140.19, for a total value of $1,401,900.00. Following the sale, the insider now directly owns 18,202 shares in the company, valued at approximately $2,551,738.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Neurocrine Biosciences Stock Up 0.5 %

Neurocrine Biosciences stock opened at $138.23 on Friday. The firm has a market cap of $13.91 billion, a price-to-earnings ratio of 38.08 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 52 week low of $93.28 and a 52 week high of $148.37. The business’s 50-day moving average price is $137.41 and its 200 day moving average price is $136.09.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $1.04 by ($0.62). The company had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. Equities analysts expect that Neurocrine Biosciences, Inc. will post 4.22 EPS for the current year.

Institutional Trading of Neurocrine Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of NBIX. Vestal Point Capital LP acquired a new stake in Neurocrine Biosciences during the fourth quarter worth about $105,408,000. Los Angeles Capital Management LLC grew its holdings in Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after purchasing an additional 364,986 shares during the period. Norges Bank acquired a new stake in Neurocrine Biosciences in the fourth quarter valued at approximately $35,731,000. Jacobs Levy Equity Management Inc. grew its holdings in Neurocrine Biosciences by 59.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after purchasing an additional 256,920 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Neurocrine Biosciences by 2.3% in the first quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company’s stock valued at $1,369,673,000 after purchasing an additional 220,598 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on NBIX shares. UBS Group raised their price objective on Neurocrine Biosciences from $174.00 to $193.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, April 10th. Evercore ISI started coverage on Neurocrine Biosciences in a research report on Tuesday, May 14th. They set an “outperform” rating and a $175.00 price objective on the stock. HC Wainwright raised their price objective on Neurocrine Biosciences from $150.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Finally, Wedbush reiterated an “outperform” rating and issued a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Six research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences presently has an average rating of “Moderate Buy” and an average price target of $152.00.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.